| scholarly article | Q13442814 |
| P50 | author | Franco Muggia | Q30512486 |
| P2093 | author name string | Peter G Rose | |
| Chunqiao Tian | |||
| Gynecologic Oncology Group | |||
| William P McGuire | |||
| G Larry Maxwell | |||
| G Scott Rose | |||
| Michael J Sundborg | |||
| Stephen C Rubin | |||
| William E Winter | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| gynecologic oncology | Q5625186 | ||
| P304 | page(s) | 83-89 | |
| P577 | publication date | 2007-11-19 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study | |
| P478 | volume | 26 |
| Q90663036 | 30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival |
| Q38714686 | A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection and Imaging of Cancer Tumor Cells. |
| Q39263789 | A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer |
| Q35926352 | A framework for a personalized surgical approach to ovarian cancer |
| Q35057291 | A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants |
| Q34854883 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer |
| Q45014116 | Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? |
| Q37017000 | Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer |
| Q54047420 | Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. |
| Q57903708 | Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor |
| Q40025780 | Aggressive and complex surgery for advanced ovarian cancer: an economic analysis |
| Q37489267 | An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models |
| Q38682323 | Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer |
| Q34167035 | Asian society of gynecologic oncology workshop 2010 |
| Q40920564 | Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer. |
| Q38617648 | Associations between residual disease and survival in epithelial ovarian cancer by histologic type |
| Q34299655 | BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis |
| Q91043335 | CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy |
| Q51828792 | Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer? |
| Q47588829 | Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. |
| Q91946612 | Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery |
| Q36547025 | Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review |
| Q102141700 | Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan |
| Q47281811 | Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study |
| Q46483826 | Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery. |
| Q91193210 | Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility |
| Q38063818 | Considerations in the surgical management of ovarian cancer in the elderly |
| Q37617608 | Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer |
| Q34645371 | Cucurbitacin D induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial and ovarian cancer cells |
| Q35908928 | Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer |
| Q82761568 | Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer |
| Q38193876 | Cytoreductive surgery for advanced ovarian cancer |
| Q58766386 | Cytoreductive surgery in primary advanced epithelial ovarian cancer |
| Q87505910 | Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer |
| Q43238536 | Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. |
| Q30360249 | Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 |
| Q36288013 | Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review |
| Q88440462 | Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm |
| Q38980176 | Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible |
| Q39940237 | Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells |
| Q37988243 | Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. |
| Q61452291 | Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer |
| Q46876850 | Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer |
| Q38874036 | FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited |
| Q34604042 | Fallopian tube origin of supposed ovarian high-grade serous carcinomas |
| Q48138644 | Folate-Targeted Surface-Enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detection of Microscopic Ovarian Cancer |
| Q90413942 | Gonadotropin-Releasing Hormone Receptor-Targeted Near-Infrared Fluorescence Probe for Specific Recognition and Localization of Peritoneal Metastases of Ovarian Cancer |
| Q64847268 | Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia |
| Q33758727 | HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas |
| Q35867496 | Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. |
| Q26996829 | Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer |
| Q37197458 | Impact of treatment response metrics on photodynamic therapy planning and outcomes in a three-dimensional model of ovarian cancer |
| Q30975500 | Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer |
| Q33563929 | Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas |
| Q37369523 | Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer |
| Q37149571 | Intraoperative imaging in ovarian cancer: fact or fiction? |
| Q59700416 | Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results |
| Q51174141 | Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. |
| Q35104225 | Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency |
| Q33734760 | Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma. |
| Q91941304 | Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer |
| Q38669762 | Long-term outcomes of patients with 10 or more colorectal liver metastases |
| Q30359356 | Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study |
| Q34682062 | Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum |
| Q89203988 | Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? |
| Q37684614 | Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer |
| Q38499574 | Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. |
| Q37386124 | Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis |
| Q34121226 | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q39693171 | Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells |
| Q38941559 | Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? |
| Q24234923 | Optimal primary surgical treatment for advanced epithelial ovarian cancer |
| Q46673327 | Optimal surgical debulking in uterine papillary serous carcinoma affects survival |
| Q37921207 | Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection |
| Q37540704 | Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma |
| Q37294314 | Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. |
| Q37608979 | Ovarian cancer cytoreductive surgery in the elderly |
| Q38703668 | Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter |
| Q36983114 | PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D ovarian cancer model |
| Q43435555 | Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer |
| Q92901866 | Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer |
| Q91950816 | Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival |
| Q91302542 | Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer |
| Q37842973 | Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review. |
| Q55174606 | Positive Surgical Margins in the 10 Most Common Solid Cancers. |
| Q37432638 | Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review |
| Q52986076 | Preoperative Prediction of Cardiophrenic Lymph Node Metastasis in Advanced Ovarian Cancer Using Computed Tomography. |
| Q35623804 | Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer |
| Q94586088 | Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
| Q41721778 | Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. |
| Q38260301 | Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? |
| Q43735818 | Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer |
| Q40042569 | Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group |
| Q40184556 | Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. |
| Q38737138 | Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer |
| Q47279109 | Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer. |
| Q43852073 | Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective |
| Q35475560 | Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients |
| Q90326209 | Prognostic value of radiological recurrence patterns in ovarian cancer |
| Q38661788 | Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study |
| Q57171698 | Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States |
| Q30378801 | Role of cytoreductive surgery in recurrent ovarian cancer. |
| Q83287534 | Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial |
| Q36573447 | Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers |
| Q30634871 | Sensitive β-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo |
| Q36243394 | Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival |
| Q37005812 | Short-term morbidity in transdiaphragmatic cardiophrenic lymph node resection for advanced stage gynecologic cancer |
| Q37307062 | Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. |
| Q40183666 | Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. |
| Q28069868 | Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers |
| Q87123589 | Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility |
| Q64092619 | Surgical treatment of ovarian cancer liver metastasis |
| Q34762831 | Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis |
| Q37036784 | Survivorship as an element of clinical trials in ovarian cancer |
| Q61815424 | Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy |
| Q37776738 | Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. |
| Q60046966 | The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer |
| Q97073519 | The Prevalence and associated Factors for Liver Metastases, Development and Prognosis in newly diagnosed Epithelial Ovarian Cancer: A large Population-Based Study from the SEER Database |
| Q41615167 | The Prognostic Role of Optimal Cytoreduction in Advanced, Bowel Infiltrating Ovarian Cancer |
| Q48291586 | The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer |
| Q37326018 | The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer |
| Q84290611 | The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer |
| Q30418957 | The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study |
| Q38476802 | The impact of pleural disease on the management of advanced ovarian cancer |
| Q51703765 | The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis. |
| Q38131754 | The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse. |
| Q87928047 | The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer |
| Q37832930 | The role of surgery in the management of epithelial ovarian cancer |
| Q45962258 | Transdiaphragmatic cardiophrenic lymph node resection for Stage IV ovarian cancer. |
| Q39405578 | Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. |
| Q98463162 | Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study |
| Q40160992 | What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer? |
| Q60369041 | “Surgical Apgar Score” predicts postoperative complications after cytoreduction for advanced ovarian cancer |
Search more.